Cytoglobin (CYGB) is frequently downregulated in many types of human malignancies, and its exogenous overexpression reduces proliferation of cancer cells. Despite its implied tumour suppressor (TSG) functions, its exact role in carcinogenesis remains unclear as CYGB upregulation is also associated with tumour hypoxia and aggressiveness. In this study, we explore the TSG role of CYGB, its influence on the phenotype of cancerous cells under stress conditions and the clinical significance of CYGB expression and promoter methylation in nonsmall cell lung cancer (NSCLC). DNA methylation-dependent expression silencing of CYGB is demonstrated in both clinical samples and cell lines. CYGB promoter was more frequently methylated in lung adenocarcinomas (P 5 1.4 3 10 24 ). Demethylation by 5 ′ -azadeoxycytidine partially restored CYGB expression in cell lines. Interestingly, trichostatin A triggered upregulation of CYGB expression in cancer cell lines and downregulation in non-tumourigenic ones. CYGB mRNA expression in NSCLC surgical specimens correlated with that of HIF1a and VEGFa (P < 1 3 10 24 ). Overexpression of CYGB in cancer cell lines reduced cell migration, invasion and anchorage-independent growth. Moreover, CYGB impaired cell proliferation, but only in the lung adenocarcinoma cell line (H358). Upon hydrogen peroxide treatment, CYGB protected cell viability, migratory potential and anchorage independence by attenuating oxidative injury. In hypoxia, CYGB overexpression decreased cell viability, augmented migration and anchorage independence in a cell-type-specific manner. In conclusion, CYGB revealed TSG properties in normoxia but promoted tumourigenic potential of the cells exposed to stress, suggesting a bimodal function in lung tumourigenesis, depending on cell type and microenvironmental conditions.
INTRODUCTION
Cytoglobin (CYGB) is an ubiquitously expressed haemoprotein that reversibly binds O 2 , NO and CO (1, 2) . CYGB has been proposed to be involved in oxygen transport, storage and sensing (3), collagen production (1) and cellular response to oxidative stress and hypoxia (1,4 -7) . Recently published evidence suggests that at the molecular level, CYGB acts as an NO dioxygenase (8) . From the functional point of view, CYGB has a cytoprotective role counteracting ischaemia-induced cell death (9) , oxidative stress (6, 10) , fibrotic changes (11) and loss of function in transplanted islet b-cells (12) .
CYGB has been found upregulated in fibrotic tissue (1, 13) and certain neurodegenerative disorders (14, 15) . In contrast, loss of CYGB has been implicated in the development of hereditary tylosis with oesophageal cancer (16) . Moreover, CYGB downregulation, resulting from promoter methylation and/or loss of heterozygosity, has been described in ovarian (17) , sporadic oesophageal (16) , lung (18) and head and neck malignancies (19, 20) . It has been consequently hypothesized that CYGB may function as a tumour suppressor (TSG). Indeed, CYGB has been reported to mediate reduction in the growth of lung and breast cancer cell lines in the liquid colony formation assay (21) . Nevertheless, TSG function of CYGB appears controversial, as elevated CYGB expression has been found in lung and brain metastases of alveolar soft-part sarcoma (22) , certain percentage of lung cancer (18) and head and neck cancer (20) . Accumulating evidence indicates that in malignant tissues, CYGB expression correlates to that of various hypoxia-responsive genes (20, 23, 24) .
In this study, we aimed to elucidate the function of CYGB in lung carcinogenesis by examining the TSG role of CYGB in lung cancer cell lines and its influence on the phenotype of cancerous cells under stress conditions. Also, we investigated CYGB expression and methylation profiles in a large set of non-small cell lung cancer (NSCLC) tissues and compared it to the expression of hypoxia markers and various clinicopathological parameters.
RESULTS

CYGB expression is epigenetically regulated in lung normal and cancer cell lines
CYGB mRNA and protein expression and promoter methylation were measured in 22 lung normal and cancer cell lines. Both qPCR and western blotting analysis showed that CYGB is downregulated in lung cancer cell lines, while the primary lung epithelial cells (NHBE), immortalized lung fetal fibroblasts (IMR90) and normal immortalized human bronchial epithelial cell (HBEC)/3-derived cell lines (3KT, 3KTR, 3KT53 and 3KTR53) express CYGB at a high level (Fig. 1) . CYGB promoter was methylated in 9/14 (64%) lung cancer cell lines and following HBECs: HBEC/10KT, 2KT and 3KTs with silenced p53 (Fig. 2A) .
We further tested the effect of epigenetic regulation on CYGB expression. Administration of 5 ′ azadeoxycitidine elevated (≥2-fold) CYGB expression in 17/22 (77%) cell lines analysed, including some of those, which showed no methylation within CYGB promoter (e.g. NHBE, CALU3). Trichostatin A (TSA) alone triggered CYGB upregulation in 7/14 (50%) lung cancer cell lines. Moreover, in 10/14 (71%) cancer cell lines, CYGB expression increased further after combined treatment with both agents. Interestingly, CYGB became almost universally downregulated in the normal cell lines treated with TSA (Fig. 2B) .
Based on the low levels of CYGB expression and promoter hypermethylation, we chose H358 and CALU1, as representatives of two most prevalent histological subtypes of NSCLC (adenocarcinoma and squamous cell lung carcinoma, respectively), to investigate CYGB influence on various aspects of tumour biology. These cell lines were transfected with pCMV6-Neo/ CYGB vector to restore CYGB expression (Fig. 3A) .
CYGB impact on cancer cell growth and death
The influence of CYGB on cellular growth was assessed by haemocytometer counting. Over 5 days of the experiment, we observed diminished proliferation in CYGB overexpressing clone of H358 (P , 0.03) (Fig. 3B) . In contrast, only a modest growth impairment, related to contact-dependent growth inhibition, was observed in CALU1/CYGB+ clone when compared with control (P ¼ 0.051) (Fig. 3C ). Investigating apoptosis ( Fig. 3D) , clones with modified CYGB expression did not show any noticeable activation of caspase 3/7, particularly when compared with the camptothecin-treated positive controls.
CYGB impairs anchorage independence and migration of lung cancer cell lines
CYGB overexpression led to reduction in cell tumourigenicity in both sets of clones (Fig. 3E, Supplementary Material, Fig. S1 ). In our soft agar assay, H358/Ctrl cell line produced 2193 + 71, while H358/CYGB+ formed 1102 + 108 colonies (P ¼ 0.03). Similarly, CALU1/Ctrl formed 457 + 70, while CALU1/ CYGB+: 82 + 9 colonies (P ¼ 0.03).
We observed diminished migratory potential evoked by exogenous CYGB expression (Supplementary Material, Fig. S2 ). Wound area covered by CYGB overexpressing clones was smaller than by the control (H358/CYGB+: 14.8+ 2.6% versus H358: 22.1 + 1.6%, P ¼ 0.02) (Fig. 4A ). This effect was more pronounced in CALU1 clones. While parental CALU1 covered 57.2 + 3.4% of the scratched space, CALU1/CYGB+ clone demonstrated almost complete inhibition of the migration (3.3% + 2.4, P ¼ 0.008). A similar, although statistically insignificant, trend was observed in the Boyden chamber assay (Fig. 4B ). In comparison with the control cell lines, CYGB overexpressing clones revealed decreased migration (H358/CYGB+: 11.3 + 1.3% versus H358: 23.5 + 4.2%, P ¼ 0.068 and CALU1/ CYGB+: 36.9+ 3.8% versus CALU1: 60.8 + 7.3%, P ¼ 0.109).
Moreover, we noticed a trend of CYGB-mediated reduction in cellular invasiveness through the Matrigel-coated inserts (Fig. 4C ). Control H358 cell line revealed 15.3 + 5.7% of invasion index, while H358/CYGB+ exhibited 6.0 + 2.9% (P ¼ 0.068). In CALU1 cell line, CYGB overexpression also decreased ability to invade Matrigel layer (3.0 + 0.1% versus 8.0 + 1.3% in CALU1/Ctrl cell line, P ¼ 0.068).
CYGB protects lung cancer cell lines against oxidative stress and hypoxia, but in a cell-type-specific manner
We analysed the influence of CYGB on the cancerous features of lung cancer cell lines exposed to oxidative and hypoxic stress. CYGB protein was modestly upregulated, but only in the Calu1 CYGB positive clone following overnight incubation with 300 mM H 2 O 2 or 48 h exposure to 1% O 2 (data not shown). As previously reported, CYGB overexpression attenuated the oxidant-mediated GSH depletion, which was particularly evident in the more sensitive CALU1 cell line (CALU1/Ctrl: GSH content ¼ 39.6 + 6.6% of untreated counterpart versus CALU1/CYGB+: 75.8 + 3.6%, P ¼ 0.028; H358/Ctrl: 79.0 + 5.1% versus H358/CYGB+: 92.6 + 1.5%, P ¼ 0.068) ( Fig. 5A ). Restoration of CYGB expression protected cellular viability (H358/Ctrl: 69.0 + 4.4% versus H358/CYGB+: 86.0 + 2.6%, P ¼ 0.008; CALU1/Ctrl: 38.3 + 3.4% versus CALU1/CYGB+: 58.0 + 3.4%, P ¼ 0.008) (Fig. 5B ). CYGB overexpression increased as well the ability of the cells to grow in soft agar following overnight incubation in the presence of H 2 O 2 (H358/Ctrl: 47.9 + 1.1% versus H358/CYGB+: 64.0 + 6.3%, P ¼ 0.075; CALU1/Ctrl: 11.1 + 3.1% versus 25.9 + 10.0%, P ¼ 0.028) (Fig. 5C ). Moreover, we observed protection or even increase in migration in CYGB overexpressing transfectants exposed to oxidative stress (H358/Ctrl: 86.2 + 7.1% versus H358/CYGB2: 128.7 + 9.1%, P ¼ 0.012; CALU1/Ctrl: 79.7 + 3.6% versus 102.6 + 4.5%, P ¼ 0.011) (Fig. 5D ).
Phenotypic studies in hypoxic conditions revealed that CYGB might exert a cytoprotective function, but in a cell-type-specific fashion. In the H358 CYGB overexpressing clone, oxygen deprivation had little effect on cell viability (H358/Ctrl: 42.0 + 5.9% versus H358/CYGB+: 34.8 + 2.5%, P ¼ 0.116, Fig. 6A ) and migration (H358/Ctrl: 95.9 + 2.7% versus H358/CYGB2: 98.9 + 1.7%, P ¼ 0.249, Fig. 6B ). In contrast, CYGB overexpression compromised CALU1 viability (CALU1/Ctrl: 71.8 + 7.0% versus CALU1/CYGB+: 41.3 + 2.8%, P ¼ 0.028, Fig. 6C ) and slightly enhanced its migratory potential (CALU1/ Ctrl: 93.7 + 5.0% versus CALU1/CYGB+: 118.6+ 3.7%, P ¼ 0.043, Fig. 6B ). Interestingly, anchorage independence was augmented in both CYGB overexpressing clones incubated at 1% O 2 prior to seeding into soft agar (H358/Ctrl: 60.9 + 8.8% versus H358/CYGB+: 132.0 + 7.0%, P ¼ 0.028; CALU1/Ctrl: 73.3 + 8.5% versus 167.5 + 23.9%, P ¼ 0.028) (Fig. 6C ).
CYGB in NSCLC tissue samples
In order to assess the potential clinical significance of CYGB in NSCLC, we evaluated the expression and methylation status of the gene and analysed it against various clinicopathological parameters, patient smoking status (including smoking duration and pack per year values) and hypoxic signature in NSCLC tissue samples. CYGB mRNA levels were measured by qPCR in 186 NSCLC specimens and 111 adjacent normal tissues. CYGB expression was significantly reduced in cancer (median RQ ¼ 0.5, interquartile range, IQR: 0.3-1.0) when compared with normal tissue samples (0.9, 0.5-1.8, Mann-Whitney test, P ¼ 2.3 × 10 27 ) (Fig. 7A ). In the comparison of 100 pairs of lung cancer and matched adjacent normal tissues, CYGB was found at least 2-fold downregulated in 49% and at least 2-fold upregulatedin 16% of the samples. In the methylation analysis, 163 tumour and 61 normal adjacent tissues were included. The 95% reference range (mean MtI% + 2 × SD) of the normal tissue specimens (T MtI% ¼ 11.6%) was chosen to define a hypermethylation threshold. CYGB promoter hypermethylation (MtI% . 11.6%) was observed more frequently in cancer (36/163) than in the adjacent normal tissues (1/61, Fisher's exact test, P ¼ 7 × 10 25 ) (Fig. 7B ). CYGB promoter hypermethylation was more frequent among the specimens with ≥2-fold downregulation of CYGB (median MtI% ¼ 6.0%, IQR: 4.0-13.2) when compared with those with at least 2-fold CYGB upregulation (3.4%, 2.9-7.0, MannWhitney test, P ¼ 0.005) (Fig. 7C) .
There was no association between CYGB mRNA expression or promoter methylation and patients' age, gender, smoking behaviour, pathological TNM classification and tumour differentiation. We observed, however, that CYGB promoter methylation was higher in adenocarcinomas (median MtI% (Fig. 8) . The correlation between CYGB and HIF1a mRNA levels was more profound in samples with low methylation values (MtI% , 11.6%) for CYGB promoter (r ¼ 0.657, P ¼ 1.2 × 10
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, N ¼ 108). No such difference was observed in the case of VEGFa.
DISCUSSION
The aim of this study was 2-fold: (i) to expand our previous observations on the extend of epigenetic deregulation of CYGB in primary NSCLCs and most importantly (ii) to investigate the effects of CYGB on cancer-related parameters under normoxic and stress conditions. The frequent downregulation of CYGB in NSCLC samples and its strong correlation to its promoter hypermethylation both in vitro and ex vivo confirmed previous findings in NSCLC and other human malignancies (16, 18, 20, 21) . Moreover, our data corroborate reports suggesting increased frequency of CYGB promoter hypermethylation in lung adenocarcinomas (18, 21) . Notably, we observed elevated CYGB promoter methylation in HBEC/10KT, HBEC/ 2KT and both p53 knockdowns of HBEC/3KT. HBEC lines utilized in this study represent an interesting pre-malignant model. These cells were derived from morphologically normal tissue resected as a margin during lung cancer surgery and immortalized with two oncogenes: hTERT and CDK4 (25) . Additionally, HBEC/3KT served as a progenitor cell line, which was modified to harbour KRAS V12 oncogene (in the case of HBEC/3KTR) and/or p53 silencing cassette (HBEC/3KTR53 and HBEC/ 3KT53, respectively) (26) . CYGB downregulation and higher promoter methylation in some of the HBEC cell lines support the idea that CYGB silencing through promoter hypermethylation may occur early during carcinogenesis. Although at this stage it is only a matter of speculation, the observations in HBEC/3KT p53 knockdowns may imply a potential correlation between p53 status and CYGB promoter methylation. It is of note, however, that elevated CYGB promoter methylation in HBEC/3KT with silenced p53 (MtI ¼ 25%) remained insufficient to impose restriction to CYGB expression. This observation points towards the involvement of other mechanisms in the control of CYGB expression. Our data in lung cancer cell lines suggest that promoter hypermethylation is not the only factor implicated in CYGB downregulation. Four of them exhibited decreased CYGB level despite low promoter methylation values. We further treated the cells with 5 ′ Aza-dC and/or TSA and confirmed that CYGB expression is epigenetically regulated. Interestingly, 5
′ Aza-dC induced CYGB upregulation, however, regardless of the CYGB promoter status. This suggests that certain, yet unknown factors involved in CYGB control may be silenced by DNA methylation in both cancer and normal cells. It is of note that TSA treatment induced CYGB upregulation in lung cancer cell lines but downregulation in untransformed primary and immortalized epithelial cells.
Our functional studies in two lung cancer cell lines with modified CYGB expression support the hypothesis that CYGB exerts TSG activity. This data set uniquely demonstrates that CYGB inhibits cancer cell migration, invasion and anchorage independence. We observed as well CYGB-mediated growth reduction, but only in the H358 adenocarcinoma cell line. The evidence on the CYGB impact on cancerous phenotype is largely limited. Our data confirm previous findings of inverse association between cell proliferation and CYGB expression (21) . Interestingly, both lung cancer cell lines with modified CYGB expression in the study conducted by Shivapurkar and colleagues were derived from lung adenocarcinomas (27, 28) , similarly to the H358 cell line. In addition, CYGB promoter hypermethylation was more frequent in adenocarcinomas in our study and other reports (18, 21) . Hypothetically, methylation-mediated CYGB silencing may provide more distinct growth advantage in lung adenocarcinomas than in squamous cell carcinomas of the lung. This histopathology-dependent CYGB effect on cell growth is most probably due to the massive differences in the molecular signatures of these two cancer types; however, further investigation is required to pinpoint the exact molecular dependencies.
In our normoxic functional assays, CYGB revealed negative influence on cell migration and invasiveness. Invasion, one of the cancer hallmarks and prerequisite for metastasis (29) , is a complex process involving multiple modifications in cellular behaviour, including motility (30, 31) . CYGB overexpression has been previously shown to diminish migration of NIH3T3 murine fibroblasts, which correlated with the focal accumulation of vinculin (13) . Thus, CYGB-related reduction in cell migration seems to be a universal phenomenon, which occurs in both normal and cancerous cells. Although focal distribution of vinculin was proposed to be one of the mechanisms responsible for CYGB interference with migration (13), vinculin was shown to support cell invasive properties (32) . It is likely, however, that CYGB affects various components of cytoskeleton and extracellular matrix, possibly by participating in their posttranslational modifications (hydroxylation, disulfide bridge oxidation/reduction) or altering cellular transcriptome.
Our data from normoxic experiments indicate TSG properties for CYGB in lung cancer cell lines, thus corroborating recently published report that showed high susceptibility to lung and liver cancer development in CYGB-deficient mice treated with N,N-diethylnitrosamine (33). The exact molecular mechanisms responsible for CYGB-mediated suppression of tumour features are currently unclear. Presumably, CYGB overexpression may increase O 2 consumption (5), enhance aerobic metabolism and thereby reverse the Warburg effect as it has been recently proposed for myoglobin (34) , the closest known CYGB homologue (35) . Alternatively, this anti-tumour effect may be associated with the ROS/RNS scavenging activity of CYGB (5, 6, 9, 33) . Due to mitochondrial and metabolic dysfunctions, cancer tissue might harbour elevated ROS/RNS content. Certain doses of oxidants activate adaptive responses and, consequently, survival and proliferation signalling (36) . Perhaps, CYGB lowers the overall oxidant concentration, thus, impairing the pathways implicated in carcinogenesis. It has been also demonstrated that CYGB might downregulate DNMT1 expression (21) , whereas low CYGB levels inversely correlate with normal methylation profile of several TSGs in vivo, independently of CYGB methylation status (unpublished data). Hence, CYGB may conceivably contribute to the epigenetic alterations in cancer cells inhibiting their tumourigenic potential.
The observed association between expression of CYGB and hypoxia markers in NSCLC confirms the responsiveness of CYGB to hypoxia seen in other tissue types (20, 23, 24) . These observations underline the bimodal character of CYGB expression control in malignant tissues: CYGB is silenced in certain subsets of tumours (16, 18, 20, 21) , while in the others-upregulated together with hypoxia markers (20, 23, 24) . Previous studies on CYGB association with stress conditions showed a cytoprotective effect of CYGB (6,9,12), but they did not provide much details on tumour cell biology. It is of note, however, that analogous cytoprotection was also observed in our experiments performed in the lung cancer cell lines exposed to the stress conditions. Our in vitro studies showed that CYGB might actively contribute to tumourigenic potential in the cells exposed to stress. Upon hydrogen peroxide treatment, CYGB protected cell viability, migratory potential and anchorage independence by attenuating oxidative injury. In hypoxia, CYGB overexpression decreased cell viability, augmented migration and anchorage independence, which was celltype specific. To avoid stress-induced death, tumour cells develop multiple defence mechanisms adjusting the prosurvival pathways, metabolism and redox homeostasis. These adaptive responses have been associated with tumour aggressiveness, higher chemo-and radio-resistance and poor prognosis in cancer patients (37) . From this point of view, CYGB overexpression may hypothetically be one of the factors contributing to the more aggressive, therapy resistant phenotype. Indeed, high levels of CYGB have been recently shown to be associated with chemoresistance signature in prostate cancer cell lines (38) , while CYGB deficiency was shown to sensitize glioma cell lines to chemo-and radiotherapy (39) , but no correlation with outcome was found in this analysis (data not shown). However, these observations should be evaluated in welldefined cancer patient cohorts. High CYGB expression has been linked not only with tumour hypoxia (20, 23, 24) , but also with cancer progression (40) and metastasis (22) . It still remains to be elucidated whether in advanced malignancy high levels of CYGB may actively promote tumour development in vivo or this upregulation has only a passenger character. It is of note that conducting both TSG and oncogene functions is a well-known phenomenon and similar mechanisms have already been described for other proteins (e.g. TGF-b) (41) . The putative switch between TSG and oncogene properties of CYGB is yet unknown, but the overall status of redox imbalance in the cancerous cell is likely to play the role.
In conclusion, our report provides the first evidence demonstrating that CYGB may function as a TSG, which represses cancer-specific properties, including anchorage independence, migration, invasion and, to a lesser extent, proliferation. Moreover, CYGB expression correlates with hypoxic signature in NSCLC and protects cancerous phenotype in response to stress exposure, which is most apparent in the oxidative stress experiments. TSG features in normoxic conditions and the ability to protect tumour cells from the oxidative insult suggest that CYGB may have a bimodal function in lung carcinogenesis. This bimodal functioning, however, depends on the cell type and microenvironmental conditions.
MATERIALS AND METHODS
Cell culture, transfection and treatments
Cell culture experiments utilized 22 cell lines, including 6 HBECs (provided by Prof. A. F. Gazdar & Prof. J. D. Minna) (25, 26) . The list of cell lines and routine culture conditions is presented in Supplementary Material, Table S1 . For epigenetic studies, the cells were treated with 100 nM 5 ′ -azadeoxycytidine (5 ′ Aza-dC, Sigma Aldrich) and 100 nM TSA (Sigma Aldrich), while stress conditions were induced overnight with 300 mM H 2 O 2 (Sigma Aldrich) or 1% O 2 , as described previously (42) . Cells were exposed to hypoxia for 24 h to test migratory potential, for 7 days to measure cellular viability or for 5 days to pre-treat the cells prior to seeding for an anchorage independence assay. To restore CYGB expression, CALU1 and H358 cell lines were transfected with a pCMV6-Neo harbouring CYGB cDNA (Origene) utilizing Attractene Transfection Reagent (Qiagen). Stable clones were selected with 600 mg/ml G418 (Promega) and single colonies were propagated for further analysis.
Patients and samples
NSCLC and adjacent normal tissue samples were collected from 212 lung cancer patients, who underwent surgery between 1995 and 2005 at the Liverpool Heart and Chest Hospital, UK. The study was approved by the Liverpool Research Ethics Committee and all patients provided informed consent. The summary of the clinicopathological parameters in the cohort studied is presented in Supplementary Material, Table S2 . This cohort and sample collection have been previously described (42) . All the methylation and expression values were included in the analysis, even in the absence of normal, methylation or expression counterpart data for the given patient.
qPCR gene expression and promoter methylation analysis RNA and DNA extraction and quantification, reverse transcription, qPCR, bisulfite conversion, PCR and Pyrosequencing methylation analysis were conducted as previously described (43) . The qPCR, PCR and Pyrosequencing primers and PCR thermal profiles are provided in Supplementary Material, Table S3 . The fragment of CYGB promoter analysed with the Pyrosequencing assay included seven consecutive CpG sites upstream of the ATG start codon: 2604, 2612, 2614, 2617, 2623, 2627 and 2635.
Western blotting
Protein extraction, quantification and western blotting were performed as previously described (44) . After blocking, PVDF membranes were probed at 48C overnight with 1:1000 anti-CYGB mouse monoclonal Ab (Abnova) and 1:5000 antitubulin a goat Ab (Santa Cruz) and then for 1 h with secondary pAb HRP-coupled 1:15000 chicken to mouse (Abcam) and 1:5000 rabbit to goat (Abcam), respectively.
Proliferation assessment and viability assay
For the proliferation assessment, the cells were seeded in triplicate on 12-well plates (Calu1: 1 × 10 4 , H358: 5 × 10 4 ) and counted daily over 5 days of experiment with the Bright-Light TM Haemocytometer (Sigma Aldrich). For the viability tests, the cells were seeded in triplicate to form 2.5 or 50% confluent layer and incubated for 7 days at 1% hypoxia or for 24 h with 300 mM H 2 O 2 , respectively. After the treatment, the cells were counted as described above and their number was normalized to the number of untreated control cells. The assay was performed in three separate biological replicates.
Caspase 3/7 and GSH-Glow
TM Glutathione Assay
Cell apoptosis and glutathione content were evaluated using Caspase-Glo w 3/7 Assay (Promega) and GSH-Glow TM Glutathione Assay (Promega), respectively, on Genios plate reader (Tecan) according to the manufacturer's protocols. The cells were seeded on luminescent-compatible 96-well plates (H358: 1.5 × 10 4 , CALU1: 0.75 × 10 4 ). The RLU values were normalized to the total protein content measured with the DC Biorad Assay (Biorad). For the positive apoptosis control, parental cell lines were treated with 50 mM campthotecin (Sigma Aldrich). For the glutathione content assessment, the readings after overnight 300 mM H 2 O 2 treatment were normalized to untreated controls.
Wound healing assay
The cells were seeded in triplicate on 24-well plate (Calu1: 3 × 10 5 , H358: 9 × 10 5 ). Wound healing assay was performed as described previously (44) . For the stress-related experiments, the cells were incubated either at 1% hypoxia or with 300 mM H 2 O 2 for 24 h. TScratch software (45) was used to calculate cell migration rate.
Boyden chamber migration and Matrigel
TM invasion assays
The cells (1.25 × 10 5 ) were seeded on the BD BioCoat TM Matrigel TM Invasion Chambers (BD Biosciences) and control inserts (BD Bioscience) with 10% serum added to the bottom chambers as a chemoattractant. Cell migration was normalized to the total number of cells seeded per well on a parallel 48-well plate. The assay and calculations were performed according to the supplier's protocol. The cells were stained with Giemsa solution (Riedel-de Haen). Air-dried membranes were mounted on microscope slides using DPX Mountant (Diachem International). The migrating and invading cells were counted in five randomly chosen fields of duplicate membranes. The assays were performed in two biological replicates.
Soft agar assay
Anchorage-independent growth assay was performed using a double-layer soft agar method in six-well plates. The cells (1 × 10 5 ) were suspended in 2 ml 0.3% low-melting point agarose (Sigma Aldrich) diluted in culture medium and poured on the bottom layer of 0.6 agarose/50% medium. Agar plates were incubated for 4 weeks and 1 ml fresh medium was added weekly. For the stress-related experiments, the cells were pretreated for 5 days at 1% hypoxia or for 24 h with 300 mM H 2 O 2 prior to seeding for the soft agar assay. Each well was photographed using the EC Imaging System (UVP). The colonies were counted with the Launch VisionWorks TM LS software (UVP). The experiment was performed in triplicate on three separate occasions.
Statistical analysis
Non-parametric tests were used for statistical analyses (PASW Statistics 18.0 software, SPSS Inc.) as the 1-sample Kolmogorov -Smirnov test demonstrated lack of normal distribution in the continuous variables. The Wilcoxon's test was used for the pair-wise comparison between the values obtained for the transfectants and parental cell lines in the functional assays. The significance of differences for continuous data among independent groups within clinical parameters was determined with the Kruskal-Wallis and Mann -Whitney tests. Fisher's exact test was used to assess differences in frequencies among nominal variables. Bivariate correlation analysis was obtained by Spearman's test.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
